广州维力医疗器械股份有限公司 审 计 报 告 华兴审字[2025]24011820015 号 华兴会计师事务所（特殊普通合伙） w 审 计 报 告 华兴审字[2025]24011820015号 广州维力医疗器械股份有限公司全体股东： 一、审计意见 我们审计了广州维力医疗器械股份有限公司（以下简称"维力医疗"或 "公司"）财务报表，包括2024年12月31日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东 权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了维力医疗2024年12月31日的合并及母公司财务状况以及2024 年度的合并及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的 "注册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下 的责任。按照中国注册会计师职业道德守则，我们独立于维力医疗，并履行 了职业道德方面的其他责任。我们相信，我们获取的审计证据是充分、适当 的，为发表审计意见提供了基础。 三、关键审计事项 关 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,509,335,256.03, representing an 8.76% increase compared to ¥1,387,735,351.81 in 2023[20]. - Net profit attributable to shareholders for 2024 was ¥219,393,029.14, a 13.98% increase from ¥192,485,118.47 in 2023[20]. - The basic earnings per share for 2024 was ¥0.75, up 13.64% from ¥0.66 in 2023[21]. - The net cash flow from operating activities increased by 37.64% to ¥306,259,194.17 in 2024, compared to ¥222,509,302.66 in 2023[20]. - The total assets of the company at the end of 2024 were ¥2,840,682,536.11, reflecting a 9.04% increase from ¥2,605,281,433.80 in 2023[20]. - The weighted average return on equity for 2024 was 11.84%, an increase of 0.97 percentage points from 10.87% in 2023[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥210,024,675.08, a 16.94% increase from ¥179,593,881.97 in 2023[20]. - The company achieved operating revenue of 1,509.34 million yuan, a year-on-year increase of 8.76%, and a net profit attributable to shareholders of 219.39 million yuan, up 13.98%[30]. Dividend Policy - The company plans to distribute a cash dividend of 5 RMB per 10 shares to all shareholders, totaling approximately 146.43 million RMB (including tax) based on a total share capital of 292,868,018 shares as of April 24, 2025[4]. - The company has a structured salary policy that includes fixed salaries and performance-based bonuses, ensuring that employee salaries are slightly above the local industry average[157]. - The company has established a cash dividend policy, with a cash dividend amount of 146,434,009.00 RMB, which accounts for 66.75% of the net profit attributable to ordinary shareholders in the consolidated financial statements[162]. Corporate Governance - The company has received a standard unqualified audit report from Huaxing Certified Public Accountants[3]. - The company has maintained a consistent governance structure with all board members present at the board meeting[3]. - The company conducted 3 shareholder meetings during the reporting period, ensuring compliance with regulations and equal treatment of all shareholders[128]. - The company has a total of 7 board members, including 3 independent directors, and held 9 board meetings during the reporting period[129]. - The company has implemented a comprehensive product development process, but faces risks related to technological feasibility and intellectual property protection[125]. - The company has revised 16 internal control systems to align with the latest regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange[132]. Market Position and Strategy - The company is a leading player in the domestic medical catheter industry, holding a significant market share in the urinary and anesthesia sectors, and has participated in drafting multiple industry standards[39]. - The company has established a presence in over 5,000 hospitals across all provinces in China, including more than 1,000 top-tier hospitals, and has obtained over 500 medical device registrations globally[39]. - The company is actively responding to centralized procurement policies while increasing R&D efforts to enhance new technologies and products, thereby enriching its product portfolio and overall competitiveness[45]. - The company is focusing on the development of advanced medical devices, with a significant number of products expected to be launched in the upcoming quarters, reflecting its growth strategy[91]. Research and Development - The company has applied for 5 invention patents and 35 utility model patents, with 10 invention patents and 20 utility model patents granted during the reporting period[33]. - The company’s R&D expenses increased by 17.06% to 111,112,162.68 RMB, indicating a focus on innovation[67]. - The company is committed to enhancing its R&D capabilities to support the development of new products and technologies, further strengthening its market position[45]. - The company has ongoing R&D projects, including a new type of gastrointestinal nutrition catheter, currently in the product registration phase, with a cumulative investment of 505,000 RMB[102]. Product Development and Innovation - The company has introduced new products, including a disposable catheter and an oxygen mask, with various certifications obtained during the reporting period[90]. - The company is focusing on enhancing its anesthesia product portfolio, with new items like the Endobronchial Tube and Tracheostomy Tube set to be available by mid-2024[92]. - Key products under development include visual single-lumen bronchial intubation, self-made artificial nose, and various catheterization systems, with a goal to meet clinical needs more effectively[121]. - The company is expanding its product line with new offerings such as the Oropharyngeal Airway and Oxygen Mask, registered in Germany, with expected availability by mid-2024[92]. Risk Management - The company has detailed potential risks in the report, which investors should review in the section discussing future developments and risks[5]. - The company is aware of the potential for product liability claims and is enhancing risk management to address this concern[124]. - The company faces risks related to overseas sales, including trade friction and currency fluctuations, and plans to implement measures to mitigate these risks[123]. Environmental Responsibility - The company has implemented carbon reduction measures, including optimizing fan operations to save 54,000 kWh of electricity annually[181]. - The company has made a total charitable donation of 220,000 yuan, benefiting an unspecified number of individuals[182]. - The company has established emergency response plans for environmental incidents, with documentation filed with local environmental authorities[177]. - The company has registered fixed pollution sources and is actively monitoring emissions to ensure compliance with environmental regulations[177]. Employee Relations - The company has implemented a training program focusing on enhancing the capabilities of management and employees through various training courses[158]. - The company has established a reasonable mechanism for sharing the benefits of its development with employees, adhering to principles of fair distribution and efficiency[156]. - The company’s management team has shown a commitment to increasing their shareholdings, indicating confidence in future performance[135]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue growth of 10% to 1.32 billion yuan[139]. - The company is exploring partnerships with international firms to leverage new technologies and expand its global footprint[139]. - The company plans to enhance its distribution network, aiming for a 15% improvement in delivery efficiency by the next quarter[139].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.7500 | 0.6600 | 13.64 | 0.5700 | | 每股净资产（元） | 6.44 | 6.2 | 3.87 | 5.88 | | 每股公积金(元) | 2.2 | 2.22 | -0.9 | 2.22 | | 每股未分配利润(元) | 2.83 | 2.72 | 4.04 | 2.46 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 15.09 | 13.88 | 8.72 | 13.63 | | 净利润(亿元) | 2.19 | 1.92 | 14.06 | 1.67 | | 净资产收益率(%) | 11.84 | 10.87 | 8.92 | 10.14 | 前十大流通股东累计持有： 16520.94万股，累计占流通股比： 56.61%，较上期变化： -428.02万股。 数据四舍五入，查看更多财务数据>> 二、前1 ...

Group 1 - The core viewpoint of the news highlights the current stock performance and valuation metrics of Weili Medical, indicating a low PE ratio compared to the industry average [1][3] - As of April 22, Weili Medical's stock closed at 11.26 yuan, with a 2.64% increase, and a rolling PE ratio of 15.32, marking a new low in 13 days [1] - The total market capitalization of Weili Medical is reported at 3.298 billion yuan, with an increase in the number of shareholders to 18,292, averaging a holding value of 352,800 yuan per shareholder [1] Group 2 - Weili Medical specializes in the research, production, and sales of medical devices in various fields including anesthesia, urology, and respiratory care [2] - The company reported a revenue of 1.06 billion yuan for the third quarter of 2024, reflecting an 8.53% year-on-year increase, and a net profit of 167 million yuan, up 15.85% year-on-year, with a gross margin of 44.80% [2] - In terms of industry comparison, the average PE ratio for the medical device sector is 48.08, with a median of 30.21, positioning Weili Medical at the 33rd rank within the industry [3]

证券代码：603309 证券简称：维力医疗 公告编号：2025-016 广州维力医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到广东省药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、一次性使用气传导尿动力测压导管 产品名称：一次性使用气传导尿动力测压导管 注册证编号：粤械注准 20252140541 注册人名称：广州维力医疗器械股份有限公司 有效期至：2030年04月14日 2、一次性使用气传导直肠测压导管 产品名称：一次性使用气传导直肠测压导管 注册证编号：粤械注准 20252140542 注册人名称：广州维力医疗器械股份有限公司 注册人住所：广州市番禺区化龙镇金湖工业城 C 区 4 号 生产地址：广州市番禺区化龙镇金湖工业城 C 区 4 号；广州市番禺区化龙镇国 贸大道南 45 号、47 号 结构及组成：由测压管和连接管（选配）组成。测压管分为双 ...

Core Viewpoint - The recent announcement by the U.S. government to impose "reciprocal tariffs" on Chinese goods has prompted a swift response from several medical device companies, which have indicated they have comprehensive plans and measures in place to address the situation. Despite the complex impacts on the supply chain, the long-term trend towards self-sufficiency and international expansion in the medical device sector remains optimistic [1][2][7]. Company Responses - Multiple medical device companies have reported minimal impact from the U.S. tariff policy, citing pre-existing contingency plans. For instance, Mindray Medical has proactively stocked products in the U.S. ahead of previous tariff increases, ensuring that current sales are unaffected by the new tariffs [2][8]. - Kaili Medical stated that the U.S. market contributes only 1%-2% to its revenue, and prior inventory preparations have mitigated the tariff impact. The company has a well-established overseas market presence [3][8]. - Dirui Medical anticipates that its direct exports to the U.S. will be around $150,000 in 2024, representing a negligible portion of its overall revenue. The company has also identified measures to minimize the tariff's effects [3]. - Leshi Medical indicated that the tariff impact is manageable, as its U.S. operations focus on digital chronic disease management solutions, which have established long-term customer relationships [3][8]. - Weili Medical reported that its exports to the U.S. account for about 15% of total revenue, with a stable business model due to long-term partnerships and necessary certifications [4]. Industry Trends - The Chinese medical device industry is experiencing a push towards domestic production and innovation, particularly in high-end medical imaging and core components, where reliance on imports has been significant. Recent advancements in domestic R&D are enabling some companies to gain competitive advantages [4][6]. - The Ministry of Commerce has initiated anti-dumping investigations into imported medical CT tubes, which may benefit domestic suppliers and manufacturers [5]. - The Chinese government continues to support the medical device sector, promoting high-quality development and encouraging companies to expand internationally. This includes backing for high-end medical devices and innovative technologies [6][7]. - Analysts suggest that despite the tariff challenges, there is a strong potential for domestic companies to increase market share and reduce reliance on imports, particularly in high-value consumables and in vitro diagnostics (IVD) sectors [7]. Long-term Outlook - The long-term export potential for Chinese medical device companies remains positive, with a focus on expanding into developing markets outside the U.S. Companies like Mindray Medical are looking to enhance their brand presence in these regions [8]. - Companies are diversifying their international strategies, with plans for local production and sales in emerging markets such as Mexico, which is expected to commence operations by early 2026 [8].

证券代码：603309 证券简称：维力医疗 公告编号：2025-015 广州维力医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到广东省药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 适用范围：供全麻或心肺人工复苏建立短期人工气道用 批准日期：2025年04月11日 有效期至：2030年04月10日 二、同类产品相关情况 根据国家药品监督管理局官网数据查询了解到的信息，截至目前，国内同行业 暂无其他厂家取得同类产品的医疗器械注册证书。 产品名称：一次性三通道可弯曲喉罩 注册证编号：粤械注准 20252080486 注册人名称：广州维力医疗器械股份有限公司 注册人住所：广州市番禺区化龙镇金湖工业城 C 区 4 号 生产地址：广州市番禺区化龙镇金湖工业城 C 区 4 号；广州市番禺区化龙镇国 贸大道南 45 号、47 号 结构及组成：由罩背、罩囊、通气管、接头 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-014 广州维力医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到广东省药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 适用范围：供医疗部门在胸科手术麻醉时作分隔支气管通气一次性使用。 批准日期：2025 年 04 月 08 日 有效期至：2030 年 04 月 07 日 二、同类产品相关情况 产品名称：一次性使用可视双腔支气管插管 注册证编号：粤械注准 20252080498 注册人名称：广州维力医疗器械股份有限公司 注册人住所：广州市番禺区化龙镇金湖工业城 C 区 4 号 生产地址：广州市番禺区化龙镇金湖工业城 C 区 4 号；广州市番禺区化龙镇国 贸大道南 45 号、47 号 结构及组成：由插管（管身、左/右支气管套囊、气管套囊、充气管、指示球囊、 单向阀、四通接头、四通接头盖板、连接管 ...

最新一期业绩显示，2024年三季报，公司实现营业收入10.60亿元，同比8.53%；净利润1.67亿元，同比 15.85%，销售毛利率44.80%。 4月8日，维力医疗今日收盘10.49元，下跌4.90%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到14.27倍，总市值30.72亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)31维力医疗14.2715.961.6730.72亿行业平均 44.5846.844.6999.90亿行业中值28.5527.892.1941.61亿1硕世生物-1692.50-1692.501.0634.97亿2诺唯 赞-515.13-515.132.2287.58亿3博晖创新-345.95-213.003.8153.10亿4康泰医学-258.4530.322.6450.27亿5华 大基因-188.97206.701.95192.03亿6奥精医疗-104.74-104.741.3318.98亿7睿昂基因-72.49-72.491.1310.48亿 8华大智造-52.56-52.563.94314.89亿9热景生物-48.54-48.542.6787.00亿 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)31维力医疗16.9118.911.9836.40亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11328.30亿10中红医疗-54.40-37.010.8648.44 亿11天智航-46.58-46.584.8657.34亿 来源：金融界 4月1日，维力医疗今日收盘12.43元，上涨3.58%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.91倍，创62天以来新低，总市值36.40亿元。 ...